Experts Stress Need For Final Trial Vaccine Data
"); jQuery("#212 h3").html("

"); });
2021-01-30 HKT 13:56
SAR government vaccine advisors on Saturday said they would only approve Covid vaccines for emergency use after phase three clinical trial results had been provided.
The government has placed one of its vaccine orders with mainland firm Sinovac, but plans for the first batch of this vaccine to arrive in February have been derailed after the company delayed the release of its final stage test data.
Earlier this week, the Chief Executive Carrie Lam said she had asked Beijing to provide the SAR with vaccines developed or manufactured on the mainland. Media reports said this could include vaccines manufactured by another mainland drug company, Sinopharm, with final stage data also pending.
Both firms have handed in trial data to the World Health Organization, which is now reviewing the vaccines for emergency use, although they have already been used in vaccination programmes on the mainland.
Infectious diseases specialist Professor Ivan Hung said he believed both companies would soon provide the necessary data. Hung, who is on the government advisory panel for Covid-19 vaccines, said Hong Kong's strong health service meant it could wait a little longer.
"We have to wait for the phase three results. I think the phase three results will be very, very important for the advisory panel to assess the safety, as well as the efficacy of the vaccine. There is no rush for us to jump in. We have time, and our health system remains very robust, so I think we could afford to wait for the phase three results for assessment," he said.
Another member on the advisory panel - former Controller for the Centre for Health Protection, Thomas Tsang - said vaccines would be vetted in the same manner, regardless of where they were produced.
Hong Kong has already ordered and approved a vaccine by Germany's BioNTech. Authorities have also ordered the Oxford University vaccine by Anglo-Swedish firm AstraZeneca, which the CE said is expected to arrive in Hong Kong in the second half the year.
Meanwhile, the Secretary for the Civil Service Patrick Nip, who is in charge of the government inoculation initiative, has said the vaccination programme can start once the BioNTech vaccine arrives some time in late February.
Nip said vaccination centres would be set up across the city and that they would operate daily for at least six months, between 8 am and 8 pm.
Ping An P&C And FAW Hongqi Launch Hongqi Intelligent Driving Protection Services
Ping An Property & Casualty Insurance Company of China (Ping An P&C), a subsidiary of Ping An Insurance, has pa... Read more
HKSTP European Innovation Mixer Tour Nurtures Global Ties For Hong Kong
The Hong Kong Science and Technology Parks Corporation (HKSTP), led by CEO Albert Wong, conducted the HKSTP European In... Read more
The Full List Of Fintech Unicorns In Hong Kong (2025)
Hong Kong’s fintech landscape has evolved into a dynamic force in Asia, driven by regulatory innovation, technologica... Read more
HKSTPs EPIC 2025 Competition Returns, Doubling Investment Pool To US$100M
The 9th edition of the Elevator Pitch International Competition, also known as the EPIC 2025 competition, officially op... Read more
RedotPay Secures $40 Million Series A Funding, To Advance Global Crypto Payment Solutions
RedotPay secures $40 million Series A funding, marking a major milestone for the crypto payment platform. The announcem... Read more
BOOM Hits $2 Billion In AUM, Reinvesting Into Crypto And Tokenised Securities
BOOM, a Hong Kong-based online investing platform for high-net-worth individuals, announced on 12 March 2025 that it ex... Read more